Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-23-020554
Filing Date
2023-05-10
Accepted
2023-05-10 16:18:14
Documents
64
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q rani-20230331.htm   iXBRL 10-Q 2065676
2 EX-31.1 rani-ex31_1.htm EX-31 21054
3 EX-31.2 rani-ex31_2.htm EX-31 21100
4 EX-32.1 rani-ex32_1.htm EX-32 13295
  Complete submission text file 0000950170-23-020554.txt   8950963

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT rani-20230331_lab.xml EX-101.LAB 591418
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT rani-20230331_cal.xml EX-101.CAL 41566
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT rani-20230331.xsd EX-101.SCH 70519
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT rani-20230331_def.xml EX-101.DEF 362370
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT rani-20230331_pre.xml EX-101.PRE 474779
58 EXTRACTED XBRL INSTANCE DOCUMENT rani-20230331_htm.xml XML 1675088
Mailing Address 2051 RINGWOOD AVENUE SAN JOSE CA 95131
Business Address 2051 RINGWOOD AVENUE SAN JOSE CA 95131 (408) 457-3700
Rani Therapeutics Holdings, Inc. (Filer) CIK: 0001856725 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40672 | Film No.: 23906655
SIC: 2834 Pharmaceutical Preparations